Oncology CROs: Navigating a Fragmented Landscape
Oncology remains the largest therapeutic area in clinical development, accounting for roughly one-third of the global trial pipeline. Yet sourcing a CRO with genuine oncology depth — not just a general CRO that lists cancer as one of many therapeutic areas — remains a persistent pain point for biotech clinical operations teams.
Why Oncology Demands Specialized CRO Capabilities
Modern oncology trials involve companion diagnostics, biomarker-driven enrollment, adaptive designs, and complex endpoint adjudication that generic CROs are poorly equipped to handle. A CRO that managed a straightforward cardiovascular outcomes trial may stumble on tumor measurement standardization (RECIST/iRECIST), immune-related adverse event monitoring, or central pathology review logistics.
Market Structure
The oncology CRO market broadly segments into three tiers:
- Global full-service CROs with oncology divisions
- ICON, IQVIA, Parexel, and PPD (Thermo Fisher) operate dedicated oncology units within their broader organizations. They offer scale — 40+ country reach, large site networks, and central lab integration — but oncology may represent only 15–25% of their total portfolio.
- Mid-size oncology-focused CROs
- Organizations like Ergomed (32% oncology portfolio, 470+ cancer projects), TFS HealthScience (300+ oncology trials in five years), and Novotech (Asia-Pacific, ~50% oncology) have built concentrated expertise. These firms often offer more therapeutic depth per dollar.
- Boutique oncology-exclusive CROs
- Theradex (NCI contractor since 1982), Medelis (founded by oncology KOLs including Daniel Von Hoff), and Catalyst Clinical Research (oncology-exclusive, ~1,000 staff) operate solely in cancer research. They typically offer the deepest indication-level expertise but narrower geographic footprints.
Key Selection Criteria for Oncology CROs
| Criterion | Why It Matters |
|---|---|
| Indication-specific experience | A CRO with 50 NSCLC trials will outperform one with broad but shallow oncology experience |
| Regulatory pathway expertise | Accelerated approval, breakthrough therapy, and adaptive designs require specialized regulatory teams |
| Biomarker infrastructure | Central lab capabilities for companion diagnostics, ctDNA assays, and immune profiling are increasingly table-stakes |
| Site relationships | Access to high-enrolling academic medical centers and NCI-designated cancer centers directly impacts enrollment timelines |
| Immuno-oncology protocols | irAE management, immune-related response criteria, and combination trial design require hands-on IO experience |
Emerging Trends
The oncology CRO landscape is shifting toward precision medicine integration. Precision for Medicine expanded its cell-free DNA testing panel to 200+ cancer-related genes in 2024. Decentralized trial elements — remote patient monitoring, eConsent, home nursing for oral oncology agents — are being adopted selectively, though the infusion-heavy nature of many oncology regimens limits full decentralization.
In Asia-Pacific, CROs like Novotech are capitalizing on faster enrollment rates and favorable regulatory frameworks in Australia, South Korea, and Singapore to attract biotech sponsors seeking cost-effective Phase I/II execution.